AJR InPractice
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Press Release
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beland, M. D.
Right arrow Articles by Mayo-Smith, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beland, M. D.
Right arrow Articles by Mayo-Smith, W. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
AJR 2005; 184:926-930
© American Roentgen Ray Society


Original Report

Percutaneous Cryoablation of Symptomatic Extraabdominal Metastatic Disease: Preliminary Results

Michael D. Beland1, Damian E. Dupuy1 and William W. Mayo-Smith1

1 All authors: Department of Diagnostic Imaging, Brown Medical School, Rhode Island Hospital, 593 Eddy St., Providence, RI 02903.

Received March 4, 2004; accepted after revision June 14, 2004.

 
Address correspondence to D. E. Dupuy (ddupuy{at}lifespan.org).


Abstract
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
OBJECTIVE. The objective of our study was to describe our initial experience using percutaneous cryoablation for palliation of symptomatic extraabdominal metastases or recurrent soft-tissue tumors.

CONCLUSION. Preliminary results suggest that percutaneous cryoablation may offer a minimally invasive alternative for relief of symptomatic metastatic disease in patients for whom conventional therapy failed.


Introduction
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
Intraoperative cryoablation of metastatic disease has been well documented in the liver [1]. Experience with percutaneous cryoablation has been limited because of the large applicator diameter of the earlier systems and the associated high incidence of postprocedure bleeding [2]. Percutaneous treatment of prostate cancer using sonographic guidance has been described by several authors [35]. With the development of an argon-based system, applicator diameters have decreased significantly from 8 to 2.4 mm and made percutaneous utilization of this technique at other sites more feasible. Recent literature has been published on percutaneous cryoablation of hepatic and renal tumors [68]. To our knowledge, experience with percutaneous cryoablation of recurrent or metastatic disease outside the abdomen has been very limited [9].

Recurrent local or metastatic disease to extraabdominal sites is a source of significant morbidity. Symptoms include local pain and mass effect on adjacent structures. Surgical resection of locally invasive disease is often not an option because of poorly defined margins, involvement of adjacent critical structures, inaccessible location, and comorbid conditions. Long recovery time and complications may also follow complicated surgical resections. Percutaneous therapy potentially offers these patients palliation and improved quality of life with minimal recovery time.


Subjects and Methods
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
This study was approved by the hospital institutional review board. The four patients in this study underwent consultation with a staff radiologist before booking the procedure and had normal results on preprocedure coagulation studies (prothrombin time, partial thromboplastin time, internationalized normalized ratio, platelet count). CT fluoroscopy was used for imaging guidance. Two patients received general anesthetic, and two had conscious sedation using midazolam, fentanyl, and continuous monitoring using dedicated nursing personnel according to our hospital's protocol. The procedures were performed at our institution over approximately 2 months comprising approximately 10% of our tumor ablation volume for that period of time.

Cryoablation
Cryoablation was performed using an argon-based cryoablation system (Endocare, Mountainview) and 2.4-mm percutaneous applicators. The applicators have a 5-cm active tip and create a freeze zone of approximately 5 x 1.5–2.0 cm (length x width). Up to eight applicators were placed simultaneously (range, 5–8 applicators) 2 cm apart in the patient. Temperatures were measured during the procedure with an attached thermocoupler (range, -94°C to -136°C). Placement was planned according to the size of the tumor and margin of the tumor and of destroyed bone to achieve pain palliation. Each patient underwent multiple 8- to 11-min freeze cycles, each followed by a 5-min active helium thaw. The low-density changes within the tissue were measured to approximate the size of the ablated region. Visible treatment margins were routinely extended 1 cm beyond the tumor during cryoablation. The terms "freeze zone," "ice ball," and "treatment area" are used interchangeably in the text and refer to the area of decreased density visualized on CT after the tissue has been frozen.

Patients and Treatment:
The first patient was a 57-year-old man diagnosed with rectal cancer who underwent primary resection and diverting colostomy (Table 1). Seven years later, he was diagnosed with local recurrence in the presacral region. Abdominoperoneal resection and placement of a right distal ureteral stent were performed followed by local radiation therapy. CT scans obtained 1 year later revealed an enlarging presacral mass and a chemotherapy regimen of irinotecan, 5-fluorouracil, and leucovorin was initiated. The patient subsequently developed two pulmonary metastases; each was treated twice with percutaneous radiofrequency ablation. Follow-up CT examination showed continued enlargement of the presacral mass with bony invasion and increased activity on PET.


View this table:
[in this window]
[in a new window]

 
TABLE 1 Cryoablation Data

 

The painful 9 x 5 x 7.5 cm mass was treated with CT-guided percutaneous cryoablation (Figs. 1A, 1B, 1C, 1D, and 1E) with the patient under conscious sedation. Eight cryoapplicators were placed into the mass, and two 10-min freeze–thaw cycles were performed. A 10 x 5 x 7 cm freeze zone was measured on CT performed immediately after treatment (Fig. 1B). The patient was transferred to the recovery room in stable condition and discharged after 2 hr with no immediate complications. He reported immediate improvement in preprocedure pain. Twelve months after treatment, he continues to have no pain and has not undergone follow-up imaging.



View larger version (104K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1A. —57-year-old man with metastatic rectal cancer and local presacral recurrence. Prone noncontrast CT image obtained in transaxial plane shows large presacral tumor with bone destruction (arrows).

 


View larger version (118K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1B. —57-year-old man with metastatic rectal cancer and local presacral recurrence. Cryoablation was performed on recurrent presacral rectal cancer. Prone noncontrast CT image obtained in transaxial plane shows round low-density area representing volume of frozen tissue at end of second freeze cycle.

 


View larger version (111K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1C. —57-year-old man with metastatic rectal cancer and local presacral recurrence. Photograph of procedure shows cryoapplicator position under CT fluoroscopy.

 


View larger version (48K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1D. —57-year-old man with metastatic rectal cancer and local presacral recurrence. Axial 18FDG PET image obtained at level of presacral mass before treatment shows increased activity consistent with metabolically active tumor (arrow).

 


View larger version (45K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 1E. —57-year-old man with metastatic rectal cancer and local presacral recurrence. Axial 18FDG PET image obtained at same level as D 4 months after procedure shows photopenic defect (arrow) in area of treatment, consistent with necrotic tumor.

 

The second patient was a 20-year-old woman with a nonosseous Ewing's sarcoma arising from the soft tissues adjacent to the pubic symphysis (Table 1). The 12-cm tumor was surgically resected with no reported evidence of metastatic disease. The patient refused chemotherapy and radiation therapy. Follow-up CT scans revealed no residual disease until 4 years later when a local recurrence in the pelvis was documented by sonographically guided percutaneous biopsy. The patient again refused chemotherapy and radiation therapy. Shortly thereafter, she developed abdominal pain; weight loss; and right hydronephrosis, which was treated with ureteral stent placement. CT examination 28 months later showed a 13 x 15 x 17 cm right pelvic mass with destructive changes in the right superior pubic ramus and pubic symphysis.

The patient was referred to our department for palliative CT-guided percutaneous cryoablation. With the patient under general anesthesia at her request, seven cryoapplicators were placed into the mass and an 11-min freeze–thaw cycle followed by a 5-min thaw was performed. The applicators were then repositioned, and a second 8-min freeze–thaw cycle was performed. The freeze zone was 8 x 12 x 6 cm on CT performed immediately after treatment. The patient was transferred to the recovery room in stable condition. After 2 hr of uneventful observation, she was transferred back to the medical floor for treatment of preexisting anemia and pain. She reported that her pain was improved, and she was discharged 3 days after the procedure. Four weeks after the procedure, she was ambulating and had further improvement in her pain. She died 1 month later.

The third patient was a 55-year-old woman diagnosed with adenocarcinoma of the left breast (Table 1). Modified radical mastectomy was performed with negative resection margins, and three of 10 axillary lymph nodes were positive for malignancy. She then completed six cycles of chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil and was placed on tamoxifen. She did well until 4 years later when she developed a palpable lump in the left supraclavicular region. Biopsy was positive for metastatic adenocarcinoma, consistent with breast origin. Surgical excision was performed followed by postoperative external beam radiation (total dose, 60 Gy). Ten months later, she developed left arm pain from a brachial plexopathy. Gadolinium-enhanced MRI depicted a 3 x 3 x 3 cm enhancing soft-tissue mass deep in relation to the pectoralis muscle in the region of the left brachial plexus in the area of recent radiation therapy (Fig. 2C). CT-guided biopsy confirmed metastatic adenocarcinoma.



View larger version (135K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2C. —55-year-old woman with recurrent metastatic breast cancer to left supraclavicular region with infiltration of brachial plexus after failure of local excision, chemotherapy, and radiation therapy. Sagittal T1-weighted fat-saturated contrast-enhanced image in left midaxillary line before treatment shows enhancing mass (arrows) in region of brachial plexus.

 

Patient 3 was referred for palliative treatment with CT-guided percutaneous cryoablation (Figs. 2A, 2B, 2C, and 2D), which was performed while she was under conscious sedation. The patient was advised that damage to the brachial plexus during treatment was highly likely, but she agreed to undergo the treatment because of the severe pain. Six cryoapplicators were placed into the mass, and two consecutive 8-min freeze–thaw cycles were performed. The applicators were repositioned, and a third 8-min freeze–thaw cycle was performed. A freeze zone of 7 x 5 x 6 cm was obtained (Fig. 2B). She was observed in the recovery area for 2 hr after the procedure. Before she was discharged, she reported an improvement in her left arm pain and some improvement in motor function. At a follow-up office visit, she had subsequently lost most motor function and sensation in that arm but was essentially pain-free. She was aware of this possibility before the procedure and was pleased with the treatment outcome. Follow-up MRI performed 7 weeks after treatment showed no change in tumor size with a persistent 1-cm area of enhancement surrounding the left subclavian artery (Fig. 2D). She continues to report no pain 13 months after cryoablation.



View larger version (130K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2A. —55-year-old woman with recurrent metastatic breast cancer to left supraclavicular region with infiltration of brachial plexus after failure of local excision, chemotherapy, and radiation therapy. Contrast-enhanced supine transaxial CT scan obtained before treatment shows soft-tissue mass (arrows) in region of left brachial plexus.

 


View larger version (145K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2B. —55-year-old woman with recurrent metastatic breast cancer to left supraclavicular region with infiltration of brachial plexus after failure of local excision, chemotherapy, and radiation therapy. Noncontrast supine transaxial CT image obtained during cryoablation shows applicator placement. Treatment monitoring was difficult secondary to beam hardening and regional fat.

 


View larger version (101K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Fig. 2D. —55-year-old woman with recurrent metastatic breast cancer to left supraclavicular region with infiltration of brachial plexus after failure of local excision, chemotherapy, and radiation therapy. Coned-down sagittal T1-weighted fat-saturated contrast-enhanced image obtained 7 weeks after treatment at follow-up shows subclavian artery flow void (arrowhead) with area of surrounding enhancing tissue (arrows), which likely represents residual inadequately treated tumor secondary to "cold sink" effect.

 

The fourth patient was a 49-year-old man with colon cancer (Table 1). He underwent right hemicolectomy and intraoperative radiofrequency ablation of a single 9-mm liver metastasis. He received five cycles of chemotherapy with 5-fluorouracil, leucovorin, and irinotecan. One year later, he developed pain in the medial posterior mid back and CT revealed a 4 x 7 x 8 cm soft-tissue mass causing bony destruction of the posterior right 10th and 11th ribs. Biopsy results indicated the mass was metastatic colon carcinoma. He was treated with radiation therapy (total dose, 50 Gy) and placed on a chemotherapy regimen of five cycles of 5-fluorouracil, leucovorin, and oxaliplatin. CT-guided percutaneous radiofrequency ablation of the chest wall mass was performed 1 month later. He experienced a moderate amount of procedural pain, and the treatment was terminated prematurely. Follow-up CT examination 6 months later showed an increase in size of the mass, now measuring 9 x 7.5 x 6 cm.

Because of the size of the lesion and the pain associated with the previous radiofrequency ablation, the patient was treated with CT-guided percutaneous cryoablation under laryngeal mask anesthesia. Five cryoapplicators were placed into the anterolateral component of the mass, and two 8-min freeze–thaw cycles were performed. The probes were then repositioned into the medial aspect of the mass, and two 8-min freeze–thaw cycles were repeated. A freeze zone of 9 x 8 x 8 cm was obtained. The patient was transferred to the recovery room after the procedure and observed for 2 hr. He was discharged from the hospital with no immediate complications. One week after the procedure, he reported improved tolerance of his pain, but he experienced a change in the quality of the preprocedure pain that required the addition of the analgesic gabapentin to his medical therapy for neuropathic pain. Despite improvement in pain tolerance, follow-up CT examination 3.5 months after treatment showed an increase in the craniocaudal dimension to approximately 12 cm with no change in the transverse or anteroposterior extent. The patient underwent emergency thoracic laminectomy for decompression of metastatic disease 8 months after treatment.


Results
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
Percutaneous cryoablation was performed in four patients with extraabdominal recurrent or metastatic cancer for whom surgical resection, chemotherapy, or external beam radiation therapy had failed. The treatments were performed over a period of approximately 2 months. Three of the lesions were large enough to require repositioning of the cryoapplicator and repeat treatment. Eleven total freeze cycles were performed on four lesions during four individual patient treatment sessions.

All patients tolerated the procedure well. None of the patients developed significant bleeding or vascular injury. Nerve damage to the brachial plexus did occur during treatment of the third patient. While this damage may be considered a complication, it was an expected outcome and was acceptable to the patient.

All patients had follow-up office visits or telephone contact (range, 2–13 months; median, 12.5 months) and imaging as described previously.


Discussion
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 
Pain related to recurrent or metastatic disease is a cause of significant morbidity in the patient with terminal cancer. The pain can be debilitating, especially when osseous structures are involved. Because of the multifocal nature of these tumors and the overall poor health of this group of patients, surgical resection is usually not a treatment option. In these select patients, percutaneous therapy may offer a minimally invasive treatment with a shorter recovery time than more invasive methods. Percutaneous ablative techniques such as ethanol injection and radiofrequency ablation have been well-described for the treatment of primary and metastatic disease in multiple organ systems [1014]. Percutaneous cryoablation has seen a more limited role. Treatment of prostate cancer using a percutaneous approach has shown excellent success [4, 5]. Because the size of the cryoablation applicator has decreased in recent years, percutaneous cryoablation has been increasingly used for treatment of liver metastases with both CT and MRI guidance [8, 15, 16] and for treatment of renal masses in patients with von Hippel-Lindau disease [7].

Percutaneous radiofrequency ablation of both intra- and extraabdominal primary and metastatic lesions has been described using both CT and sonographic guidance [1013]. Radiofrequency ablation offers a minimally invasive local treatment option but can be limited by local procedural pain, poor real-time visualization of treatment effects under CT guidance, and limited ablation volumes. Cryoablation offers a few specific advantages over radiofrequency ablation, such as probable decreased procedure-associated pain [17] and real-time visualization of the treatment area. Although the cryoablation applicators are slightly less expensive than the radiofrequency ablation electrodes, depending on tumor size, more applicators are used in cryoablation offsetting the cost advantage. In addition, the start-up costs of a cryoablation system are slightly higher because argon gas is required.

The ability to observe the treatment margins in real-time is an essential attribute of an effective imaging-guided treatment technique. Multiple prior articles have described the appearance of frozen tissue on sonography, CT, and MRI [3, 9, 1820]. The use of sonographic guidance is limited because only the near edge of frozen tissue is adequately visualized given that sound waves do not adequately penetrate frozen tissue. This problem is not a significant one intraoperatively because the probe can be moved into other planes, but it poses significant difficulty when the percutaneous approach is used. Conversely, CT guidance with CT fluoroscopy offers clear visualization of the entire treatment margin in real-time, which is critical when treating lesions near vital organs, hollow viscera, and the biliary tree and urinary tract where posttreatment strictures can occur. The margins of the frozen tissue seen on CT do not represent the true margins of tumor necrosis because temperatures at the advancing outer edge of the ice ball are sublethal [21]. Therefore, we attempted to extend the margin of frozen tissue 1 cm beyond the tumor margins seen on CT.

The use of multiple small (2.4-mm) tip applicators allows substantial control over the size and shape of the treatment area. This is especially important when treating lesions with irregular margins. We placed applicators at a distance of approximately 2 cm apart within the lesion and attempted to place applicators within 1 cm of the edge of visible tumor to achieve adequate treatment margins. The freeze zones blended smoothly between applicators giving the area of frozen tissue a homogeneous appearance on posttreatment CT. We did have difficulty achieving adequate freezing of a tumor adjacent to a large vessel in the third patient. This is thought to be secondary to what we refer to as the "cold sink" effect where the continuous inflow of blood at body temperature does not allow adequate freezing of the adjacent tissue. This was confirmed on follow-up imaging where there was residual enhancing tumor adjacent to the left subclavian artery (Fig. 2D).

Our study is limited by a small patient population and limited imaging follow-up. Further investigation with larger treatment groups, longterm follow-up, and the use of a standardized pain-reporting scale is necessary for proof of efficacy. The patients in our report had already failed conventional therapy and had very advanced disease with large locally aggressive lesions. Our preliminary results suggest that percutaneous imaging-guided cryoablation is well tolerated and may play a role in the treatment of symptomatic local metastases.


References
Top
Abstract
Introduction
Subjects and Methods
Results
Discussion
References
 

  1. Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg2002; 89:1396 -1401[Medline]
  2. De Sanctis JT, Goldberg SN, Mueller PR. Percutaneous treatment of hepatic neoplasms: a review of current techniques. Cardiovasc Intervent Radiol 1998;21:273 -296[Medline]
  3. Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer1993; 72:1291 -1299[Medline]
  4. Saliken JC, Donnelly BJ, Rewcastle JC. The evolution and state of modern technology for prostate cryosurgery. Urology2002; 60[2 suppl 1]:26 -33[Medline]
  5. Onik G, Narayan P, Vaughan D, Dineen M, Brunelle R. Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer: a new approach to preserving potency. Urology2002; 60:109 -114
  6. Silverman SG, Tuncali K, Adams DF, et al. MR imaging-guided percutaneous cryoablation of liver tumors: initial experience. Radiology2000; 217:657 -664[Abstract/Free Full Text]
  7. Shingleton WB, Sewell PE Jr. Percutaneous renal cryoablation of renal tumors in patients with von Hippel-Lindau disease. J Urol 2002;167:1268 -1270[Medline]
  8. Mala T, Edwin B, Samset E, et al. Magnetic resonance guided percutaneous cryoablation of hepatic tumours. Eur J Surg 2001;167:610 -617[Medline]
  9. Saliken JC, McKinnon JG, Gray R. CT for monitoring cryoablation. AJR 1996;166:853 -855[Free Full Text]
  10. Mayo-Smith WW, Dupuy DE, Parikh PM, Pezzullo JA, Cronan JJ. Imaging-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients. AJR 2003;180:1503 -1508[Abstract/Free Full Text]
  11. Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities. Part I. J Vasc Interv Radiol 2001;12:1021 -1032[Medline]
  12. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities. Part II. J Vasc Interv Radiol 2001;12:1135 -1148[Medline]
  13. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology2000; 217:633 -646[Abstract/Free Full Text]
  14. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology1999; 210:655 -661[Abstract/Free Full Text]
  15. Huang A, McCall JM, Weston MD, et al. Phase I study of percutaneous cryotherapy for colorectal liver metastases. Br J Surg2002; 89:303 -310[Medline]
  16. Lee FT, Chosy SG, Littrup PJ, Warner TF, Kuhlman JE, Mahvi DM. CT-monitored percutaneous cryoablation in a pig liver model: pilot study. Radiology1999; 211:687 -692[Abstract/Free Full Text]
  17. Timmermans C, Ayers GM, Crijns C, Rodriguez L. Randomized study comparing radiofrequency ablation with cryoablation for the treatment of atrial flutter with emphasis on pain perception. Circulation2003; 107:1250 -1252[Abstract/Free Full Text]
  18. Onik G, Cooper C, Goldberg HI, et al. Ultrasonic characteristics of frozen liver. Cryobiology 1984;21 : 321-328[Medline]
  19. Kuszyk BS, Choti MA, Urban BA, et al. Hepatic tumors treated by cryosurgery: normal CT appearance. AJR1996; 166:363 -368[Abstract/Free Full Text]
  20. McLoughlin RF, Saliken JF, McKinnon G, Wiseman D, Temple W. CT of the liver after cryoablation of hepatic metastases: imaging findings. AJR 1995;165:329 -332[Abstract/Free Full Text]
  21. Saliken J, Cohen J, Miller R, Rothert M. Laboratory evaluation of ice around a 3mm AccuProbe. Cryobiology1995; 32:285 -295

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Neuroradiol.Home page
T.C. Schirmang, L.M. Davis, P.T. Nigri, and D.E. Dupuy
Solitary Fibrous Tumor of the Buccal Space: Treatment with Percutaneous Cryoablation
AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1728 - 1730.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Liapi and J.-F. H. Geschwind
Transcatheter and Ablative Therapeutic Approaches for Solid Malignancies
J. Clin. Oncol., March 10, 2007; 25(8): 978 - 986.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. R. Callstrom, T. D. Atwell, J. W. Charboneau, M. A. Farrell, M. P. Goetz, J. Rubin, J. A. Sloan, P. J. Novotny, T. J. Welch, T. P. Maus, et al.
Painful Metastases Involving Bone: Percutaneous Image-guided Cryoablation--Prospective Trial Interim Analysis.
Radiology, November 1, 2006; 241(2): 572 - 580.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Press Release
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beland, M. D.
Right arrow Articles by Mayo-Smith, W. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beland, M. D.
Right arrow Articles by Mayo-Smith, W. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS